バイオヘブンに関するコメント

it's number 4, $アミリックス・ファーマシューティカルズ(AMLX.US)$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $バイオジェン(BIIB.US)$ all time low 2 USD
no 2. $ニューロクライン・バイオサイエンシス(NBIX.US)$ all time low 1.9 USD
no 3. $バイオヘブン(BHVN.US)$ all time low 7 USD
no5. $アルジェンX(ARGX.US)$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...

$バイオヘブン(BHVN.US)$ buying at bid at 43ish over valued

Compared to the success of $イーライリリー(LLY.US)$ and $NOVO NORDISK A/S(NONOF.US)$, $ファイザー(PFE.US)$ had a rocky start in launching its weight-loss pill. Last December, Pfizer announced that it would discontinue the development of a twice-daily iteration of its weight loss medication danuglipron, due to its unacceptable side effect profile as revealed by a Phase 2b trial. Before that, Pfizer gave up an oral dr...

$バイオヘブン(BHVN.US)$
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $ゼノン・ファーマシューティカルズ(XENE.US)$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more

$バイオヘブン(BHVN.US)$ easy short to 37

$バイオヘブン(BHVN.US)$ out from game done with few gains

$バイオヘブン(BHVN.US)$ volume resistance at 44.05 M,  picking up in million looks good to hold here !

$バイオヘブン(BHVN.US)$ bought 2.1K lets run !